Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) Short Interest Up 21.0% in February

Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) was the recipient of a large growth in short interest during the month of February. As of February 13th, there was short interest totaling 2,538,952 shares, a growth of 21.0% from the January 29th total of 2,098,448 shares. Based on an average daily volume of 1,518,433 shares, the days-to-cover ratio is currently 1.7 days. Currently, 0.3% of the shares of the stock are short sold. Currently, 0.3% of the shares of the stock are short sold. Based on an average daily volume of 1,518,433 shares, the days-to-cover ratio is currently 1.7 days.

Elite Pharmaceuticals Stock Performance

OTCMKTS ELTP opened at $0.40 on Friday. Elite Pharmaceuticals has a twelve month low of $0.27 and a twelve month high of $0.82. The business’s 50-day moving average price is $0.44 and its 200 day moving average price is $0.54. The company has a current ratio of 7.34, a quick ratio of 5.44 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $430.80 million, a PE ratio of 13.34 and a beta of 0.35.

Elite Pharmaceuticals (OTCMKTS:ELTP) last announced its quarterly earnings data on Tuesday, February 17th. The specialty pharmaceutical company reported $0.01 earnings per share (EPS) for the quarter. The company had revenue of $31.59 million during the quarter. Elite Pharmaceuticals had a net margin of 30.98% and a return on equity of 47.93%.

About Elite Pharmaceuticals

Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.

Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.